Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer Full Text
BMC Cancer, 08/21/2012
Niethammer AG et al. – The results of this study shall provide the first data regarding the safety and immunogenicity of the oral anti–vascular endothelial growth factor receptor 2 (VEGFR–2) vaccine VXM01 in cancer patients. They will also define the recommended dose for phase II and provide the basis for further clinical evaluation, which may also include additional cancer indications.